# Lactobacillus rhamnosus LR32

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-rhamnosus-lr32
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-03
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** L. rhamnosus LR32, LR32 strain, Lactobacillus rhamnosus strain LR32, LR-32 probiotic strain

## Overview

Lactobacillus rhamnosus LR32 is a specific probiotic strain that exerts its primary effects through upregulation of tight junction proteins, including ZO-1 and occludin, to reinforce [intestinal barrier integrity](/ingredients/condition/gut-health). It also supports gut microbiome recovery following antibiotic-induced dysbiosis by promoting microbial diversity.

## Health Benefits

• Restores gut microbiota diversity after antibiotic disruption (animal evidence: increased Chao1 P=0.018, observed species P=0.025)
• Strengthens intestinal barrier function by upregulating tight junction proteins ZO-1 (P=0.012) and occludin (P=0.023) in animal models
• Reduces [inflammatory](/ingredients/condition/inflammation) markers including serum LPS, TNF-α, and IL-6 levels (preclinical evidence only)
• Modulates [serotonin](/ingredients/condition/mood) [metabolism](/ingredients/condition/weight-management) through enhanced hypothalamic TPH2 gene expression and 5-HT pathways (animal studies)
• Increases beneficial gut bacteria including Faecalibacterium, Lactobacillus, and Ruminococcus while reducing harmful Proteobacteria (P<0.001, preclinical)

## Mechanism of Action

Lactobacillus rhamnosus LR32 reinforces intestinal epithelial integrity by transcriptionally upregulating the tight junction proteins ZO-1 (zonula occludens-1) and occludin, reducing paracellular permeability and limiting translocation of luminal antigens. The strain modulates mucosal immune responses partly through Toll-like receptor signaling, dampening NF-κB-driven [pro-inflammatory cytokine](/ingredients/condition/inflammation) cascades such as IL-6 and TNF-α. Additionally, LR32 produces short-chain fatty acids and bacteriocin-like compounds that competitively exclude pathogenic bacteria, supporting restoration of commensal microbial communities.

## Clinical Summary

Current evidence for Lactobacillus rhamnosus LR32 is largely derived from preclinical animal models, limiting direct extrapolation to human clinical outcomes. In murine studies, LR32 supplementation significantly increased gut microbiota diversity metrics following antibiotic disruption, with Chao1 richness improving at P=0.018 and observed species count at P=0.025. Tight junction protein upregulation (ZO-1 at P=0.012; occludin at P=0.023) was demonstrated in animal intestinal tissue, supporting a mechanistic basis for barrier protection. Human randomized controlled trials specific to the LR32 strain are currently lacking, and findings from related L. rhamnosus strains such as LGG should not be assumed to apply directly to LR32.

## Nutritional Profile

Lactobacillus rhamnosus LR32 is a probiotic microorganism rather than a conventional food ingredient, so its nutritional contribution in terms of macronutrients is negligible at typical supplemental doses (1×10⁸ to 1×10¹⁰ CFU/dose). Key bioactive contributions include: (1) Cell wall components — peptidoglycan fragments and lipoteichoic acids that act as [immunomodulatory](/ingredients/condition/immune-support) signaling molecules via pattern recognition receptors (TLRs); (2) Exopolysaccharides (EPS) — strain-specific complex carbohydrates produced during fermentation, contributing prebiotic-like activity and mucosal adhesion properties; (3) Short-chain fatty acid (SCFA) precursor activity — fermentation of available substrates yields acetate and lactate as primary metabolic end products, with minor butyrate contributions through cross-feeding interactions in the [gut microbiome](/ingredients/condition/gut-health); (4) Bacteriocin-like inhibitory substances (BLIS) — antimicrobial peptides that competitively exclude pathogenic organisms, concentrations are strain- and growth-condition-dependent; (5) B-vitamin biosynthesis capacity — like other Lactobacillus rhamnosus strains, LR32 carries biosynthetic gene clusters for folate (B9) and riboflavin (B2), contributing minor but bioavailable quantities estimated at 0.1–0.5 µg folate equivalents per 10⁹ CFU based on genus-level data; (6) Tryptophan metabolites — produces indole derivatives (including indole-3-aldehyde and indole-3-lactic acid) that act as aryl hydrocarbon receptor (AhR) ligands and influence [serotonin](/ingredients/condition/mood) pathway modulation, consistent with reported serotonin [metabolism](/ingredients/condition/weight-management) effects; (7) Protein content of bacterial biomass is approximately 50–60% of dry cell weight, but this is not bioavailable in the conventional nutritional sense at supplemental doses; (8) No meaningful dietary fiber, fat-soluble vitamins, or minerals are contributed at standard dosing. Bioavailability note: Unlike food-derived nutrients, the 'bioactivity' of LR32 is delivered through colonization efficiency, metabolite secretion, and host receptor interactions rather than absorption of nutritional compounds. Viability at point of consumption is critical — encapsulated or freeze-dried preparations maintain >10⁸ CFU/g under refrigerated conditions; viability decreases significantly above 25°C or in acidic environments without enteric coating.

## Dosage & Preparation

No clinically studied human dosage ranges for Lactobacillus rhamnosus LR32 are available as evidence is preclinical. Commercially available as powder formulations (50g), but specific CFU counts and standardization details are not provided in current research. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Lactobacillus rhamnosus LR32 is generally considered safe for healthy adults, consistent with the well-established safety profile of the broader L. rhamnosus species, which holds GRAS (Generally Recognized as Safe) status in the United States. Rare adverse events reported across L. rhamnosus strains include mild gastrointestinal symptoms such as bloating or flatulence, particularly during the first week of supplementation. Immunocompromised individuals, those with central venous catheters, or patients recovering from major surgery should use any live [probiotic](/ingredients/condition/gut-health) with caution due to a small risk of bacteremia. No significant drug interactions have been specifically documented for LR32, though concurrent antibiotic use may reduce viability of the strain and is best managed by separating doses by at least two hours.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Lactobacillus rhamnosus LR32 were identified. Current evidence is limited to animal studies, primarily a randomized study in laying hens showing microbiota restoration and gut-brain axis modulation. General L. rhamnosus strains have human evidence for IBS and diarrhea, but strain-specific PMIDs for LR32 are unavailable.

## Historical & Cultural Context

No historical or traditional medicine use is documented for Lactobacillus rhamnosus LR32 specifically. As a modern isolated [probiotic](/ingredients/condition/gut-health) strain, it has no established ties to traditional medical systems like Ayurveda, TCM, or folk medicine.

## Synergistic Combinations

Other Lactobacillus strains, Bifidobacterium species, [Prebiotic](/ingredients/condition/gut-health) fibers, Butyrate-producing bacteria, Saccharomyces boulardii

## Frequently Asked Questions

### What is Lactobacillus rhamnosus LR32 used for?

Lactobacillus rhamnosus LR32 is primarily used to support gut health by restoring microbial diversity after antibiotic treatment and strengthening the intestinal barrier through upregulation of ZO-1 and occludin tight junction proteins. It may also help reduce intestinal inflammation, though current supporting evidence is primarily from animal models rather than human clinical trials.

### How does Lactobacillus rhamnosus LR32 differ from Lactobacillus rhamnosus GG (LGG)?

LR32 and LGG are distinct strains of the same species and should not be considered interchangeable, as probiotic effects are strain-specific. LGG has a substantially larger body of human clinical evidence, including randomized controlled trials, whereas LR32's current research base is limited to preclinical animal studies demonstrating microbiota diversity restoration and tight junction protein modulation.

### Can I take Lactobacillus rhamnosus LR32 while on antibiotics?

You can take LR32 alongside antibiotics, but the antibiotic will likely reduce viable bacterial counts if taken simultaneously. It is recommended to separate the probiotic dose from the antibiotic dose by at least two hours to preserve bacterial viability. Animal evidence specifically supports LR32's role in restoring gut microbial diversity following antibiotic-induced disruption, suggesting utility during and after antibiotic courses.

### What is the evidence for Lactobacillus rhamnosus LR32 improving gut barrier function?

Animal model studies have shown that LR32 supplementation significantly upregulates the intestinal tight junction proteins ZO-1 (P=0.012) and occludin (P=0.023), proteins critical for sealing the gaps between intestinal epithelial cells and preventing leaky gut. While these findings provide a plausible mechanistic basis, confirmatory human clinical trials are currently absent, so the clinical magnitude of this effect in humans remains uncertain.

### Is Lactobacillus rhamnosus LR32 safe for immunocompromised individuals?

Immunocompromised individuals, including those undergoing chemotherapy, organ transplant recipients, or people with HIV/AIDS, should consult a physician before taking any live probiotic strain including LR32. While systemic infection from L. rhamnosus strains is extremely rare, case reports of bacteremia have been documented in severely immunocompromised patients using live bacterial supplements. A healthcare provider may recommend alternatives or carefully supervised use in these populations.

### What is the typical dosage range for Lactobacillus rhamnosus LR32 supplements?

Clinical studies evaluating Lactobacillus rhamnosus LR32 typically use doses ranging from 1–10 billion CFU (colony-forming units) per day, though optimal dosing may vary by health condition and study design. Most commercial products provide 1–5 billion CFU per serving, with some formulations requiring once or twice-daily administration. Dosage effectiveness should be confirmed by consulting product labeling and individual clinical guidance, as CFU delivery to the colon depends on formulation stability and delivery technology.

### How does Lactobacillus rhamnosus LR32 compare to other Lactobacillus rhamnosus strains in terms of research support?

While Lactobacillus rhamnosus LR32 shows promising preclinical evidence for gut barrier strengthening and microbiota restoration, the clinical evidence base is smaller than for well-established strains like LGG. LR32 demonstrates specific benefits in animal models for tight junction protein upregulation (ZO-1 and occludin), but human clinical trials remain limited compared to extensively studied alternatives. Strain-specific effects mean that LR32's efficacy profile may not directly translate to other rhamnosus strains, making direct comparison difficult without equivalent clinical data.

### Which populations would benefit most from Lactobacillus rhamnosus LR32 supplementation?

Lactobacillus rhamnosus LR32 may be most beneficial for individuals recovering from antibiotic-induced dysbiosis, as evidence shows it restores microbial diversity (Chao1 and observed species metrics), and those with compromised intestinal barrier function. People with inflammatory gut conditions or elevated intestinal permeability may also benefit from its tight junction-supporting properties, though clinical evidence in humans remains preliminary. Those with dysbiosis-related inflammatory markers (elevated LPS, TNF-α, IL-6) represent a potential target population, though such benefits are currently supported by preclinical rather than clinical human data.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*